Antibody Therapy of Cancer

Antibody marks the cancer cell and makes it easier for the immune system to find. The monoclonal antibody drug rituximab (Rituxan) attaches to a specific protein (CD20) found only on B cells, one type of white blood cell. Certain types of lymphomas arise from these same B cells. monoclonal antibodies can also function by attenuating hyperactive growth signals neo angiogenesis. A monoclonal antibody can be conjugated to a radioactive particle that will ensure directed delivery to the cancer cell and slow and long release of the radiation, hence maximizing chances of positive outcome and minimizing non-specific damaging exposure to radiation.

The advent of monoclonal antibody technology has made it possible to raise antibodies against specific antigens, such as the unusual antigens present on tumor surfaces.

    Related Conference of Antibody Therapy of Cancer

    November 2-3, 2017

    9th World Congress and Expo on Immunology

    Atlanta, Georgia, USA
    November 02-03, 2017

    9th World Congress on Immunity, Inflammation and Immunotherapies

    Atlanta, Georgia, USA
    November 06-07, 2017

    2nd International Conference on Autoimmunity

    Frankfurt, Germany
    November 08-09, 2017

    3rd Antibodies and Bio Therapeutics Congress & B2B

    Las Vegas, Nevada, USA
    November 13-14, 2017

    5th International Conference on HIV/AIDS, STDs and STIs

    Las Vegas, Nevada, USA
    Dec 14-15, 2017

    World Immunology Congress

    Dubai, UAE
    April 19-20, 2018

    7th World Congress on Immunology

    Amsterdam, Netherlands
    May 28-29, 2018

    World Congress on Allergy and Immunotherapy

    Osaka, Japan

    9th European Immunology Conference

    June 14-16, 2018 Rome, Italy
    July 05-07, 2018

    EuroSciCon Conference on Immunology Conference 2018

    Vienna, Austria
    July 12-13, 2018

    5th International Conference on Parasitology

    Paris, France

    Antibody Therapy of Cancer Conference Speakers

    Recommended Sessions

    Related Journals

    Are you interested in